semaglutide gastric intestinal obstruction lawsuit in louisiana FDA Updates Ozempic Label to Include Blocked Intestines as Side Effect Lawsuit Alleges Ozempic Caused Ileus,

V., Crews, B

GLP1 is a gut-derived polypeptide released from the intestinal L cells, capable of stimulating glucose-dependent insulin secretion and inhibiting food intake by acting on the pancreas and brain, respectively

Off-label use might present additional risks not listed on the drugs label

It points to two groups of symptoms that deserve closer attention: reproductive issues such as irregular menstrual cycles and temperature-related effects like chills and hot flashes

Tumores tiroideos

Non-diabetic individuals with obesity experienced an average weight reduction of 11.85% from their baseline when using semaglutide, compared to those on a placebo